RATIO-ATOMOXETINE CAPSULE

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE)

থেকে পাওয়া:

TEVA CANADA LIMITED

এটিসি কোড:

N06BA09

INN (আন্তর্জাতিক নাম):

ATOMOXETINE

ডোজ:

25MG

ফার্মাসিউটিকাল ফর্ম:

CAPSULE

রচনা:

ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE) 25MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

30/100/500

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0150434003; AHFS:

অনুমোদন অবস্থা:

CANCELLED PRE MARKET

অনুমোদন তারিখ:

2015-10-16

পণ্য বৈশিষ্ট্য

_ _
_ratio-ATOMOXETINE (Atomoxetine Hydrochloride) _
_1 of 52 _
PRODUCT MONOGRAPH
PR
RATIO-ATOMOXETINE
Atomoxetine Hydrochloride Capsules
10mg, 18mg, 25mg, 40mg and 60mg atomoxetine (as atomoxetine
hydrochloride)
Selective Norepinephrine Reuptake Inhibitor for
Attention-Deficit/Hyperactivity
Disorder (ADHD)
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada M1B 2K9
www.tevacanada.com
Date of Revision :
May 31, 2012
SUBMISSION CONTROL NO.: 153586
_ _
_ratio-ATOMOXETINE (Atomoxetine Hydrochloride) _
_2 of 52 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................... 3
SUMMARY PRODUCT INFORMATION
.............................................................. 3
INDICATIONS AND CLINICAL USE
.................................................................... 3
Special Diagnostic Considerations
............................................................................
3
Need for Comprehensive Treatment Program
........................................................... 4
CONTRAINDICATIONS
.........................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................
5
ADVERSE REACTIONS
........................................................................................
12
DRUG ABUSE AND DEPENDENCE
................................................................... 21
DRUG INTERACTIONS
........................................................................................
22
DOSAGE AND ADMINISTRATION
....................................................................
24
OVERDOSAGE
......................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
.................................................. 27
STORAGE AND STABILITY
................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................... 32